These microorganisms must remain viable, active, and present in sufficient numbers, with the total count of the starter culture microorganisms being at least 10 7 colony-forming units (cfu) per gram in the final product, up to the date of minimum durability (54)
Potential for treating other conditions While GLP-1 drugs will continue to evolve in weight loss treatment, studies have also shown promise in treating Alzheimers and Parkinsons, possibly as a result of these drugs ability to regulate insulin levels and calm inflammation
Im ordering again
But it turns out, as recent research has confirmed, that COVID-19 may also increase the risk of type 2 diabetes
Ozempic (semaglutide) and Mounjaro (tirzepatide) These are FDA approved for type 2 diabetes, not for weight loss
Gastrointestinal side effects affect approximately 2540% of people starting GLP-1 receptor agonist therapy, with stomach pain ranking among the most frequently reported concerns